Diagnosis of blood loss is multifaceted and relies heavily on laboratory testing. By refining the analysis and reporting of common laboratory data, the laboratory can further help clinicians to diagnose and characterize blood loss in an efficient and timely manner. Hematocrit results are commonly available due to the multitude of indications for ordering. We first examined the hematocrit characteristics at a population level with simple descriptive statistics, stratified by patient setting. Our institution measured 358,080 hematocrits during a one-year period. When plotted as a histogram, these values comprised a clearly bimodal distribution. Separating hematocrits by inpatient vs outpatient produced two unimodal distributions, with modes occurring at 26% and 39%, respectively. A hematocrit of 26% is the usual transfusion threshold for red cells at our institution. Because we have a relatively high number of inpatients who are transfusion dependent, the mode of the inpatient hematocrits is not surprising. Oncology, cardiology, OB/GYN, and the transplant services contributed most to low hematocrit values.
Diagnosis of blood loss is multifaceted and relies heavily on laboratory testing. By refining the analysis and reporting of common laboratory data, the laboratory can further help clinicians to diagnose and characterize blood loss in an efficient and timely manner. Hematocrit results are commonly available due to the multitude of indications for ordering. We first examined the hematocrit characteristics at a population level with simple descriptive statistics, stratified by patient setting. Our institution measured 358,080 hematocrits during a one-year period. When plotted as a histogram, these values comprised a clearly bimodal distribution. Separating hematocrits by inpatient vs outpatient produced two unimodal distributions, with modes occurring at 26% and 39%, respectively. A hematocrit of 26% is the usual transfusion threshold for red cells at our institution. Because we have a relatively high number of inpatients who are transfusion dependent, the mode of the inpatient hematocrits is not surprising. Oncology, cardiology, OB/GYN, and the transplant services contributed most to low hematocrit values. Delta values, defined as the difference between a pair of sequential hematocrit values, are used by our laboratory to alert personnel to possible instrument and sampling errors, or actual large drops in patient hematocrits. We found that two standard deviations below the mean delta value (-8%) corresponded well with the threshold already used by our lab to raise flags. While useful, delta values fail to communicate the rate of change ("hematocrit velocity"), which can conceivably be used to identify dropping hematocrit before a large drop has occurred. Velocities can be simply calculated as v = (h2 -h1)/Δt. By default, most instruments report hematocrit in 1% increments; such reporting contributes significantly to velocity error for small time intervals, Δt. After eliminating time intervals <1 h, the velocity distribution, which was not distributed normally, was found to be centered nearly at zero with an interquartile range of -0.042%/h to 0.015%/h and a standard deviation of 0.27%/h (6.6%/day). Delta values and hematocrit velocities were correlated with transfusions to estimate probability of transfusion as a function of recent delta value or velocity. Transfusions most commonly occurred for hematocrits of 26%, delta values of -2%, and velocities of -0.1%/h. With big data comes big responsibility to maximize the utility of commonly measured values. We have demonstrated how characterization of hematocrits and derived values (delta values, velocities) can be used to set thresholds for flagging laboratory values, estimate rate of hematocrit loss, and correlate with subsequent transfusion. Further characterization of hematocrit based on patient population and refined derived values might be used to guide hematocrit measurement frequency and predicting need for specific transfusion blood products. Such questions will be the subject of future work. Deficiency in 24-hydroxylase caused by pathogenic CYP24A1 gene mutations abrogates 24,25OH2D synthesis, leading to hypercalcemia and predisposing patients to hypercalciuria, nephrolithiasis, and nephrocalcinosis. An inappropriately high (>80) 25OHD/24,25OH2D ratio (r25/24) determined by liquid chromatography tandem mass spectrometry (LC-MS/MS) has been suggested to serve as a rapid biochemical screen for 24-hydroxylase deficiency, which can precede availability of genetic testing results by weeks (Molin et al, 2015, JCEM) . Conversely, normal 24-hydroxylase activity has been described in conjunction with r25/24<80. However, the evidence of correlation between r25/24 and CYP24A1 genotype has been largely limited to familial studies or case reports. Objectives: The objective of this study was to explore the relationship between the r25/24 determined in a clinical laboratory setting and CYP24A1 genotype to better define the ratio that is a reliable surrogate for 24-hydroxylase deficiency. Methods: Total 25OHD and total 24,25OH2D concentrations were measured in patient sera (n = 97) by LC-MS/MS using previously reported methods (Netzel et al, 2011, Clinical Chemistry; Ketha et al, 2016, Clinical Chemistry) . DNA was purified from residual sera using QIAamp circulating nucleic acid extraction kit (Qiagen). The mutation status of 11 exons and 3'-UTR region of the CYP24A1 gene was evaluated with Sanger sequencing using BigDye Terminator (ABI BigDyeTerminator TM v1.1). Sequencing traces were analyzed manually with Mutation Surveyor software. A comprehensive literature search was conducted for reported CYP24A1 genotypes and associated 25OHD/24,25OH2D ratios. Results: Of the 97 patient sera, 22 (23%) had an r25/24>80. Among the 23 sera with CYP24A1 genotyping, 18 (78%) had r25/24 >80, and five (22%) had r25/24 <80. Eight unique pathogenic variations were found across six of 11 exons, with mutations on exons 2 and 9 being most common, in line with previous reports. Cases with r25/24 >80 (range 103-700) were found to harbor two pathogenic mutations (n = 10), homozygous mutations (n = 1), heterozygous mutations (n = 4), and no pathogenic mutations (n = 3). The average 24,25OHD2D concentrations and r25/24 in patients with at least two pathogenic variants were 0.2 ng/mL (IQR 0.1-0.3) and 287 (IQR 159-357). All other patients had significantly higher 24,25OH2D concentrations (2.3 ng/mL [IQR 1.2-3.8]), and significantly lower r25/24 (14 [IQR 10-21]) (P values < .001, Mann Whitney U test), respectively. Specimens with r25/24 <80 were found to harbor heterozygous pathogenic mutations (n = 3), or no pathogenic variants (n = 2).
Conclusions:
The relationship between r25/24 and CYP24A1 genotype is complex and multifactorial. Two pathogenic mutations were found in 61% of patients with elevated r25/24 (>103), supporting 24-hydroxylase deficiency diagnosis.
High Frequency of False-Positive Results of Lupus Anticoagulant Tests in Patients Receiving Argatroban

Julian Villalba, Elizabeth M. Van Cott; Massachusetts General Hospital, Boston
Introduction: Argatroban is a direct, selective thrombin inhibitor. The US Food and Drug Administration licensed its use for patients with or at risk for heparin-induced thrombocytopenia (HIT) undergoing percutaneous coronary intervention. Argatroban and other direct-thrombin inhibitors are being used more often for prophylaxis and treatment of thrombosis in known or suspected HIT. Patients receiving argatroban would be likely to undergo hypercoagulation testing because they are likely to have had a thrombotic event. Thus, we sought to determine if argatroban could interfere with lupus anticoagulant (LA) testing. Methods: To evaluate the effect of argatroban on LA testing, we prospectively and consecutively assessed LA testing for patients when they were receiving argatroban and compared the results with when they were not receiving argatroban to determine the interference of argatroban on these assays. LA testing included the lupus anticoagulant-sensitive activated partial thromboplastin time (PTT-LA) assay, 1:1 mixing, and the confirmatory hexagonal phase (Staclot-LA) assay. We determined the rate of false-positive results of LA tests on ex vivo specimens from patients treated with argatroban. Results: Over a 2.5 year period, 42 patients receiving argatroban were identified at our hospital. Once a patient was determined to be receiving argatroban, an additional plasma specimen before starting argatroban therapy or after discontinuation of argatroban therapy was retrieved. For specimens collected after argatroban was discontinued, a thrombin time was performed and was demonstrated to be normal to ensure that argatroban was no longer present. A total of 100 samples with or without argatroban were available for testing. All patients had a prolonged activated partial thromboplastin time(aPTT) when they were receiving argatroban (mean ± SD: 65.2 ± 23.6 seconds). Interestingly, all argatroban specimens but one showed significant prolongations in the PTT-LA (mean ± SD: 88 ± 32.4 seconds). LA testing was confirmed true-positive in 38% (16/42) of samples from patients not receiving argatroban. Among them, 100% were also positive when on argatroban (mean delta ± SD: off argatroban 16.9 ± 9.6 seconds, on argatroban 30.4 ± 15.4 seconds). For patients without LA, the mean PTT-LA significantly increased when on argatroban (mean ± SD: off argatroban 41.6 ± 12 seconds, on argatroban 87.6 ± 32.1). Among them, all but one (25/26) became false positive when on argatroban (mean delta ± SD: off argatroban 3 ± 2.5 seconds, on argatroban 25.8 ± 17.7 seconds), leading to a 96.1% false-positive rate in confirmatory testing. Hence, only one argatroban specimen was identified as a true-negative for LA testing. These effects were seen even in specimens containing subtherapeutic argatroban levels. Conclusions: Argatroban significantly affects LA testing. The rate of false-positive results in LA testing is unacceptably high in patients receiving argatroban. Clinicians should be advised that LA testing for patients receiving argatroban is not accurate.
Clinical Utility of the Modified Prothrombin Time Test As Part of an Emergency Stroke Panel
Ashley Eckel, Daniel Sabath;University of Washington, Seattle
Stroke is a leading cause of serious, long-term disability and the fifth leading cause of death in the United States. Thrombolytic therapy, specifically with intravenous (IV) recombinant tissue plasminogen activator (tPA) can restore cerebral blood flow in some patients with acute ischemic stroke and may lead to improvement or resolution of neurologic defects. The administration of tPA is highly time sensitive, as the medication must be given within 3.0-4.5 hours of symptom onset. In addition to the time limitations,
